Takeda Pharma to start Hib vaccine Phase III trial in Japan
Earlier in May 2009, Takeda signed an agreement with Novartis, under which the Switzerland-based Novartis has provided license rights to market and distribute Hib vaccine TAK-816 (Vaxem Hib)
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.